On this page
Quick Reference
Overview and Recommendations
Background
- •Gastric cancer systemic therapy is selected according to the clinical setting, perioperative, adjuvant, advanced first-line, and subsequent lines, each with distinct goals and evidence-based regimens. Biomarker stratification (MSI, PD-L1 CPS, CLDN18.2, HER2) is essential before choosing a first-line regimen.
- •Perioperative chemotherapy for resectable locally advanced gastric cancer (LAGC) improves survival. The PRODIGY trial demonstrated that neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) followed by D2 surgery and adjuvant S-1 significantly improved PFS versus surgery plus adjuvant S-1 alone (adjusted HR 0.70, 95% CI 0.52-0.95); updated OS data confirmed a benefit (HR 0.72, 8-year OS 63.0% vs 55.1%). The DRAGON IV/CAP 05 trial showed that adding camrelizumab and low-dose rivoceranib to perioperative SOX increased pCR from 5.0% to 18.3% (OR 4.5, P<0.0001).
- •MSI-high status carries distinct implications. In a 1,556-patient meta-analysis, MSI-high was a favorable prognostic factor but a negative predictive factor for perioperative chemotherapy, patients with MSI-high tumors did not benefit from chemotherapy plus surgery (5-year DFS 70% vs 77%, HR 1.27). Conversely, neoadjuvant immune checkpoint inhibitors (ICIs) yield high response rates in localized dMMR/MSI-H gastric cancer, with a pooled pCR of 41.9% (95% CI 33.2%-51.1%) and grade 3-4 immune-related adverse events in only 6.7%.
- •For advanced HER2-negative gastric cancer, the standard first-line therapy is a platinum/fluoropyrimidine doublet plus nivolumab for patients with PD-L1 CPS ≥5. CheckMate 649 reported 5-year OS rates of 16% vs 6% (HR 0.71, 95% CI 0.61-0.81) and ORR of 58% vs 46% in the CPS≥5 population. For CLDN18.2-positive tumors (moderate-to-strong expression in ≥40% of cells), the FAST trial showed that adding zolbetuximab (800/600 mg/m²) to EOX improved PFS (HR 0.44, 95% CI 0.29-0.67) and OS (HR 0.55, 95% CI 0.39-0.77).
- •HER2-directed therapy remains a cornerstone. Trastuzumab plus chemotherapy is standard first-line for HER2-positive advanced gastric cancer (ToGA trial: median OS 13.8 vs 11.1 months; HR 0.74). The KEYNOTE-811 trial demonstrated that adding pembrolizumab to trastuzumab and chemotherapy further improves PFS and OS. For third-line, trastuzumab deruxtecan (T-DXd) 6.4 mg/kg every 3 weeks produced an ORR of 51% vs 14% and improved OS (12.5 vs 8.4 months; HR 0.59) in DESTINY-Gastric01.
- •Second-line chemotherapy (docetaxel or irinotecan) reduces the risk of death by 36% (HR 0.64, 95% CI 0.52-0.79) versus best supportive care. For third-line therapy, apatinib, a VEGFR2 TKI, improved OS (6.5 vs 4.7 months, HR 0.709) and PFS (2.6 vs 1.8 months, HR 0.444) in a placebo-controlled phase III trial. The RINDBeRG trial found no OS benefit for continuing ramucirumab beyond progression (HR 0.91, 95% CI 0.74-1.13).
Evaluation
- •Suspect need for systemic therapy in any patient with advanced gastric cancer (unresectable, metastatic) or high-risk resectable disease (T3/T4 or node-positive). Also consider perioperative therapy for locally advanced resectable disease.
- •Ask about symptoms: dysphagia, early satiety, weight loss, abdominal pain, nausea/vomiting, melena or hematemesis. Assess performance status using ECOG scale, PS ≥2 predicts worse outcomes with PD-1 blockade.
- •Examine for cachexia (defined as >5% weight loss in 6 months or >2% if BMI <20 kg/m²), ascites, palpable abdominal mass, lymphadenopathy (especially left supraclavicular), and signs of peritoneal carcinomatosis.
- •Order baseline labs: CBC with differential, comprehensive metabolic panel (including renal and hepatic function), LDH, CRP, albumin. Calculate modified Glasgow prognostic score (mGPS) from CRP and albumin for prognosis.
- •Order imaging: CT chest/abdomen/pelvis with oral and IV contrast for staging. Consider PET-CT if metastatic disease is suspected but not confirmed on CT. For perioperative candidates, staging laparoscopy is recommended to rule out peritoneal metastases.
- •Mandatory biomarker testing on tumor tissue: HER2 IHC (with FISH if IHC 2+), PD-L1 combined positive score (CPS) using 22C3 or 28-8 pharmDx assay, MSI/MMR status (IHC for MLH1, MSH2, MSH6, PMS2 or PCR), and CLDN18.2 IHC (if available). Testing should be performed on the most recent biopsy or resection specimen.
- •Assess nutritional status: document weight loss percentage, calculate BMI. Refer to dietitian if cachexia is present, early dietetic referral reduces weight loss (median 0% vs 2% at 3 months).
- •Evaluate comorbidities that affect treatment tolerance: cardiac disease (risk of cardiotoxicity with anti-VEGF agents), renal impairment (oxaliplatin preferred over cisplatin if eGFR <60 mL/min), hepatic impairment, autoimmune disease (risk of irAE with ICIs).
- •Consider histologic subtype: diffuse-type histology is associated with worse event-free and overall survival compared with intestinal type (HR 1.94). Tumor location (GEJ vs gastric) may influence chemotherapy backbone choice.
- •For patients with peritoneal metastases, consider intraperitoneal therapy options (e.g., IP paclitaxel) or HIPEC in clinical trials. The GASTRIPEC-I trial showed PFS benefit with HIPEC after cytoreductive surgery (7.1 vs 3.5 months) but no OS benefit overall.
- •Also consider: age <60 years (independent predictor of poor survival in REAL-2), neutrophil-to-lymphocyte ratio >3.0 (HR 1.73 for OS), and baseline health-related quality of life (worse social functioning and nausea associated with worse survival).
Management
- •For resectable LAGC, administer perioperative chemotherapy: DOS regimen (docetaxel 60 mg/m² IV day 1, oxaliplatin 100 mg/m² IV day 1, S-1 80 mg/m²/day PO days 1-14, every 3 weeks for 3 cycles pre- and post-op) or FLOT regimen (docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m², 5-FU 2600 mg/m² over 24h, every 2 weeks for 4 pre- and 4 post-op cycles).
- •For MSI-H resectable disease, consider neoadjuvant immunotherapy instead of chemotherapy: nivolumab 240 mg IV every 2 weeks or 480 mg every 4 weeks for 3-4 cycles before surgery. Pooled pCR is 41.9% with grade 3-4 irAE in only 6.7%.
- •After D2 resection in Asia, adjuvant chemotherapy is standard: S-1 80 mg/m²/day PO days 1-14 plus docetaxel 40 mg/m² IV day 1, every 3 weeks for 6 cycles for stage III disease (JACCRO GC-07). For Western patients with suboptimal lymphadenectomy (D0/D1), consider adjuvant chemoradiotherapy per INT-0116: bolus FU 425 mg/m²/d and leucovorin 20 mg/m²/d before, during (FU 400 mg/m²/d), and after 45 Gy radiotherapy.
- •For advanced HER2-negative, PD-L1 CPS ≥5: initiate nivolumab 360 mg IV every 3 weeks plus capecitabine 1000 mg/m² PO BID days 1-14 plus oxaliplatin 130 mg/m² IV day 1, every 3 weeks (CAPOX backbone). Alternative: nivolumab 240 mg IV plus FOLFOX every 2 weeks. Continue until progression or unacceptable toxicity.
- •For PD-L1 CPS 1-4: pembrolizumab 200 mg IV every 3 weeks plus investigator's choice of fluoropyrimidine/platinum chemotherapy (e.g., CAPOX or FOLFOX). KEYNOTE-859 showed median OS 12.9 vs 11.5 months (HR 0.78).
- •For PD-L1 CPS <1: chemotherapy alone, FOLFOX (oxaliplatin 85 mg/m², leucovorin 400 mg/m², 5-FU 400 mg/m² bolus then 2400 mg/m² over 46h, every 2 weeks) or CAPOX (oxaliplatin 130 mg/m² day 1, capecitabine 1000 mg/m² BID days 1-14, every 3 weeks) or S-1 plus cisplatin (S-1 80 mg/m²/day days 1-14, cisplatin 60 mg/m² day 1, every 3 weeks).
- •For CLDN18.2-positive tumors (moderate-to-strong expression in ≥40% of cells): zolbetuximab 800 mg/m² IV loading dose, then 600 mg/m² IV every 3 weeks plus EOX (epirubicin 50 mg/m² day 1, oxaliplatin 130 mg/m² day 1, capecitabine 625 mg/m² BID days 1-21, every 3 weeks).
- •For HER2-positive advanced disease: trastuzumab 8 mg/kg IV loading, then 6 mg/kg every 3 weeks plus cisplatin 80 mg/m² IV day 1 plus capecitabine 1000 mg/m² PO BID days 1-14, every 3 weeks. Consider adding pembrolizumab 200 mg IV every 3 weeks based on KEYNOTE-811.
- •Second-line therapy after progression on platinum-fluoropyrimidine: paclitaxel 80 mg/m² IV weekly (3 weeks on, 1 week off) with or without ramucirumab 8 mg/kg IV every 2 weeks. Do not continue ramucirumab beyond progression (RINDBeRG negative).
- •Third-line therapy: for HER2-positive, trastuzumab deruxtecan 6.4 mg/kg IV every 3 weeks (DESTINY-Gastric01). For HER2-negative, apatinib 850 mg PO daily (VEGFR2 TKI). Monitor for hand-foot syndrome, proteinuria, hypertension.
- •What NOT to do: Do not use FAMTX or FEMTX regimens (no benefit). Do not omit immunotherapy for PD-L1 CPS ≥5 patients without contraindications (absolute OS benefit 10% at 5 years). Do not use bevacizumab in perioperative setting (increased anastomotic leaks). Do not use non-dihydropyridine CCBs with chemotherapy (no role).
- •Monitor: CBC and CMP before each cycle. For oxaliplatin, assess for peripheral neuropathy; consider dose reduction or switch if grade ≥2. For ICIs, monitor thyroid function (TSH, free T4) every 3 cycles and watch for immune-related adverse events (colitis, pneumonitis, hepatitis, dermatitis). For trastuzumab and anti-VEGF agents, monitor blood pressure and cardiac function (echocardiogram every 3 months).
- •Supportive care: For neutropenia, consider G-CSF prophylaxis in high-risk patients (comorbidities: COPD, CHF, HIV, autoimmune disease, renal disease). For febrile neutropenia, hospitalize and start broad-spectrum antibiotics. For hand-foot syndrome, use emollients, avoid heat/friction, consider dose interruption. For diarrhea, aggressive hydration, loperamide; for irinotecan-related, consider octreotide if severe.
- •When to refer: to medical oncology for systemic therapy initiation and management; to surgical oncology for resection evaluation; to palliative care for symptom management and advance care planning; to dietitian for cachexia; to cardiology if cardiotoxicity suspected.
- •Discharge criteria after first cycle: patient tolerating regimen, no febrile neutropenia, adequate oral intake, pain controlled, and follow-up imaging scheduled (CT every 2-3 months). Provide education on side effects and when to seek emergency care.
Board Review — High Yield
- •CheckMate 649, Nivolumab + chemotherapy improved 5-year OS from 6% to 16% in PD-L1 CPS ≥5 advanced gastric cancer (HR 0.71).
- •ToGA trial, Trastuzumab + cisplatin/fluoropyrimidine improved OS in HER2-positive advanced gastric cancer (13.8 vs 11.1 months; HR 0.74).
- •DESTINY-Gastric01, Trastuzumab deruxtecan 6.4 mg/kg every 3 weeks produced 51% ORR vs 14% in third-line HER2-positive disease.
- •PRODIGY trial, Neoadjuvant DOS (docetaxel, oxaliplatin, S-1) improved PFS in resectable LAGC (HR 0.70).
- •MSI-H paradox, MSI-high is favorable prognostic but negative predictive for perioperative chemotherapy; neoadjuvant ICI yields pCR ~42%.
- •KEYNOTE-859, Pembrolizumab + chemotherapy improved OS in HER2-negative advanced gastric cancer (12.9 vs 11.5 months; HR 0.78).
- •AVAGAST trial, Bevacizumab + chemotherapy improved PFS but not OS in first-line advanced disease; no role in perioperative setting.
- •RINDBeRG trial, Continuing ramucirumab beyond progression with irinotecan did not improve OS (HR 0.91).
- •GASTRIPEC-I, HIPEC after cytoreductive surgery improved PFS (7.1 vs 3.5 months) but not OS in peritoneal metastases.
- •Cachexia, Affects 48% of patients; >5% weight loss in 6 months independently predicts worse OS (HR 1.52); early dietitian referral reduces weight loss.
Deep Dive — Evidence Details
Setting-Based Framework
- ▸Perioperative chemotherapy improves survival in resectable LAGC with evidence from PRODIGY and DRAGON IV; MSI-H status is a negative predictive factor for chemotherapy and a strong indication for neoadjuvant ICIs.
- ▸Adjuvant S-1 plus docetaxel is a standard for stage III in Asia (JACCRO GC-07); adjuvant chemoradiation (INT-0116) remains a standard in the West.
- ▸First-line advanced therapy is biomarker-driven: nivolumab for PD-L1 CPS≥5, zolbetuximab for CLDN18.2-positive, and ICIs for MSI-H.
Systemic therapy for is selected according to the clinical setting, perioperative, adjuvant, advanced first-line, and subsequent lines, each with distinct goals and evidence-based regimens. Biomarker stratification (MSI, PD-L1 CPS, CLDN18.2, HER2) is essential before choosing a first-line regimen.
Neoadjuvant and Perioperative Chemotherapy
For resectable locally advanced gastric cancer (LAGC), perioperative chemotherapy improves survival. The PRODIGY trial demonstrated that neoadjuvant , , and S-1 (DOS) followed by D2 surgery and adjuvant S-1 significantly improved PFS versus surgery plus adjuvant S-1 alone (adjusted HR 0.70, 95% CI 0.52-0.95) [8]A1b; updated OS data confirmed a benefit (HR 0.72, 8-year OS 63.0% vs 55.1%) [12]A1b. The DRAGON IV/CAP 05 trial showed that adding and low-dose to perioperative SOX increased pCR from 5.0% to 18.3% (OR 4.5, P<0.0001) [13]A1b; longer-term survival data are awaited.
MSI-high status carries distinct implications. In a 1,556-patient meta-analysis, MSI-high was a favorable prognostic factor but a negative predictive factor for perioperative chemotherapy, patients with MSI-high tumors did not benefit from chemotherapy plus surgery (5-year DFS 70% vs 77%, HR 1.27) [6]B2a. Conversely, neoadjuvant immune checkpoint inhibitors (ICIs) yield high response rates in localized dMMR/MSI-H gastric cancer, with a pooled pCR of 41.9% (95% CI 33.2%-51.1%) and grade 3-4 immune-related adverse events in only 6.7% [19]C4. Longer ICI exposure (≥3 months) was associated with higher pCR (50.2% vs 28.4%, P=0.003) [19]C4.
Adjuvant Chemotherapy
After D2 resection, adjuvant chemotherapy is standard in Asia. The ARTIST 2 trial compared S-1, SOX, and SOX plus chemoradiotherapy (SOXRT) in node-positive stage II/III disease. The 3-year DFS was 64.8% with S-1, 74.3% with SOX (HR 0.692, P=0.042), and 72.8% with SOXRT (HR 0.724, P=0.074 vs S-1) [4]A1b; adding radiotherapy did not improve DFS (HR 0.971, P=0.879) [4]A1b. The JACCRO GC-07 trial showed that adding docetaxel to S-1 improved 3-year RFS (66% vs 50%, HR 0.632) in stage III disease, establishing S-1 plus docetaxel as a standard [9]A1b. In Western populations, the INT-0116 trial established adjuvant chemoradiotherapy (fluorouracil/leucovorin plus 45 Gy) for T3+ and/or node-positive disease after R0 resection, with persistent OS benefit at 10-year follow-up (HR 1.32, 95% CI 1.10-1.60) [11]A1b.
Advanced First-Line Therapy
For advanced HER2-negative gastric cancer, the standard first-line therapy is a platinum/fluoropyrimidine doublet plus for patients with PD-L1 CPS ≥5. CheckMate 649 reported 5-year OS rates of 16% vs 6% (HR 0.71, 95% CI 0.61-0.81) and ORR of 58% vs 46% in the CPS≥5 population [3]A1b. For CLDN18.2-positive tumors (moderate-to-strong expression in ≥40% of cells), the FAST trial showed that adding zolbetuximab (800/600 mg/m²) to EOX improved PFS (HR 0.44, 95% CI 0.29-0.67) and OS (HR 0.55, 95% CI 0.39-0.77) [16]B2b. Triplet chemotherapy (anthracycline- or docetaxel-based) modestly improves OS over doublets (HR 0.78, 95% CI 0.65-0.92) but with increased toxicity [20]B3b.
Second-Line and Beyond
A meta-analysis of three randomized trials confirmed that second-line chemotherapy (docetaxel or ) reduces the risk of death by 36% (HR 0.64, 95% CI 0.52-0.79) versus best supportive care [1]B2a. For third-line therapy, apatinib, a VEGFR2 TKI, improved OS (6.5 vs 4.7 months, HR 0.709) and PFS (2.6 vs 1.8 months, HR 0.444) in a placebo-controlled phase III trial [15]A1b. The RINDBeRG trial found no OS benefit for continuing beyond progression (HR 0.91, 95% CI 0.74-1.13) but PFS was improved (HR 0.72) [14]A1b.
Peritoneal Metastases
The PHOENIX-GC trial showed a trend toward improved OS with intraperitoneal plus S-1 versus plus S-1 (median OS 17.7 vs 15.2 months, HR 0.72) [10]A1b. The GASTRIPEC-I trial demonstrated that adding HIPEC to cytoreductive surgery improved PFS (7.1 vs 3.5 months) but not OS (14.9 months both groups) [7]A1b. In a prespecified subgroup with complete cytoreduction, HIPEC significantly improved OS [7]A1b.
Biomarker testing (MSI, PD-L1 CPS, CLDN18.2, HER2) is essential to guide first-line therapy selection. The role of concurrent chemoradiotherapy is discussed in the next section.
Pearl: In resectable gastric cancer, the choice of perioperative versus adjuvant-only therapy depends on geography and histology; MSI-H status should prompt consideration of neoadjuvant immunotherapy rather than chemotherapy.
| Setting | Trial | Regimen | Primary End Point | Key Result |
|---|---|---|---|---|
| Neoadjuvant (investigational) | DRAGON IV [13]A1b | SOX + camrelizumab + rivoceranib vs SOX | pCR | 18.3% vs 5.0% (OR 4.5) |
| Adjuvant (Asia) | ARTIST 2 [4]A1b | S-1 vs SOX vs SOXRT | 3-year DFS | 64.8%, 74.3%, 72.8% |
| Adjuvant (Asia) | JACCRO GC-07 [9]A1b | S-1 + docetaxel vs S-1 | 3-year RFS | 66% vs 50% (HR 0.632) |
| Adjuvant (West) | INT-0116 [11]A1b | FU/LV + 45 Gy vs observation | OS | HR 1.32 (favoring chemoradiation) |
| Advanced first-line | CheckMate 649 [3]A1b | Nivolumab + chemo vs chemo (CPS≥5) | OS | HR 0.71; 5-year OS 16% vs 6% |
| Advanced first-line | FAST [16]B2b | Zolbetuximab + EOX vs EOX (CLDN18.2+) | PFS | HR 0.44 |
| Second-line | Meta-analysis [1]B2a | Docetaxel or irinotecan vs BSC | OS | HR 0.64 |
| Third-line | Apatinib trial [15]A1b | Apatinib vs placebo | OS | 6.5 vs 4.7 months (HR 0.709) |
| Peritoneal | PHOENIX-GC [10]A1b | IP/IV paclitaxel + S-1 vs SP | OS | 17.7 vs 15.2 months (HR 0.72) |
| Peritoneal | GASTRIPEC-I [7]A1b | CRS + HIPEC vs CRS alone | OS | 14.9 months both groups; PFS improved |
Concurrent Chemotherapy with RT
- ▸Adjuvant chemoradiotherapy (CRT) improves survival after suboptimal (D0/D1) lymphadenectomy (INT-0116), but after D2 dissection, CRT does not add benefit over chemotherapy alone (ARTIST, CRITICS, Wang et al.).
- ▸Fluoropyrimidines (5-FU, capecitabine) are the standard radiosensitizers; oxaliplatin-based regimens are alternatives for patients with renal impairment.
- ▸Neoadjuvant CRT increases pathologic complete response but does not improve disease-free or overall survival compared with neoadjuvant chemotherapy alone.
Building on the setting-based framework, the integration of concurrent chemotherapy with radiotherapy (CRT) has been tested across multiple randomized trials, with outcomes heavily influenced by surgical quality and patient selection.
Adjuvant Chemoradiotherapy: Landmark Evidence
The INT-0116 trial established adjuvant CRT as a standard after suboptimal lymphadenectomy. Patients with T3/T4 or node-positive received bolus fluorouracil (FU) 425 mg/m²/d and leucovorin 20 mg/m²/d before, during (FU 400 mg/m²/d), and after 45 Gy radiotherapy. With >10-year follow-up, CRT improved overall survival (OS) (HR 1.32; 95% CI 1.10-1.60; P=0.0046) and relapse-free survival (HR 1.51; 95% CI 1.25-1.83; P<0.001) versus surgery alone [11]A1b. Benefit was robust across most subgroups except diffuse histology [11]A1b.
After D2 lymphadenectomy, the ARTIST trial compared six cycles of plus (XP) versus two cycles of XP followed by 45 Gy CRT with capecitabine 1650 mg/m²/d, then two more XP cycles. Overall, CRT did not significantly improve disease-free survival (DFS) (HR 0.740; 95% CI 0.520-1.050) [36]A1b[38]A1b. However, in the node-positive subgroup, CRT improved DFS (HR 0.6865; 95% CI 0.4735-0.9952) [38]A1b. The subsequent ARTIST 2 trial (not yet reported) focuses on this subgroup.
CALGB 80101 tested whether replacing FU/LV with , cisplatin, and infusional FU (ECF) before and after CRT improved outcomes. Five-year OS was identical at 44% in both arms (HR 0.98; 95% CI 0.78-1.24) [37]A1b.
The CRITICS trial, after preoperative chemotherapy, randomized patients to postoperative chemotherapy or CRT. In per-protocol analysis, chemotherapy alone yielded superior 5-year OS (57.9% vs 45.5%; adjusted HR 1.62; 95% CI 1.24-2.12; P=0.0004) [27]A1b.
More recently, a Chinese trial (Wang et al.) randomized 620 patients with T4 or node-positive disease after D2 to six cycles of S-1 plus (SOX) versus one cycle of SOX followed by 50.4 Gy CRT with concurrent S-1 50 mg twice daily, then three more SOX cycles. Three-year DFS was similar (70.5% vs 69.3%; HR 0.98; 95% CI 0.73-1.33) [33]A1b.
Neoadjuvant Chemoradiotherapy
Liu et al. compared preoperative SOX alone versus one cycle of SOX followed by CRT (45-50.4 Gy) then another SOX cycle before surgery. Three-year DFS was indistinguishable (53.6% vs 53.9%; HR 1.02; 95% CI 0.70-1.50), though pathologic complete response was higher with CRT (12.0% vs 2.1%) [34]A1b.
Chemotherapy Agents Used Concurrently
Fluoropyrimidines (infusional FU or oral capecitabine) are the standard radiosensitizers. Cisplatin-based doublets (XP, CF) have been used, but oxaliplatin-based regimens (SOX) offer an alternative for patients with renal impairment, as demonstrated in the Wang and Liu trials [33]A1b[34]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Adjuvant CRT after D2 resection | NCCN: Consider for node-positive disease | ESMO: Not routinely recommended | Moderate | CRT benefit limited to patients with inadequate lymphadenectomy or high-risk features |
| Optimal concurrent agent | /capecitabine | Cisplatin-based doublet | Weak | No randomized comparison; choice based on toxicity profile |
Pearl: After D2 gastrectomy with modern chemotherapy, adding radiotherapy does not improve survival; the benefit of adjuvant CRT is confined to patients with suboptimal lymph node dissection (D0/D1) or node-positive disease, where locoregional failure risk is highest.
| Trial | Surgery | Regimen | RT Dose | Primary Endpoint | Result |
|---|---|---|---|---|---|
| INT-0116 [11]A1b | D0/D1 (54% < D1) | FU/LV ± RT | 45 Gy | OS | HR 1.32 (95% CI 1.10-1.60) favoring CRT |
| ARTIST [36]A1b[38]A1b | D2 | XP ± RT | 45 Gy | DFS | HR 0.74 (95% CI 0.52-1.05); benefit in node-positive |
| CALGB 80101 [37]A1b | Mixed (55% ≥15 nodes) | FU/LV vs ECF + RT | 45 Gy | OS | 5-yr OS 44% vs 44% (HR 0.98) |
| CRITICS [27]A1b | D2 (after preop chemo) | Postop chemo vs CRT | 45 Gy | OS | 5-yr OS 57.9% vs 45.5% favoring chemo (HR 1.62) |
| Wang et al. [33]A1b | D2 | SOX ± RT | 50.4 Gy | 3-yr DFS | 70.5% vs 69.3% (HR 0.98) |
Chemotherapy Regimens
- ▸First-line regimen selection is driven by HER2 status and PD-L1 CPS; nivolumab plus chemotherapy is standard for CPS ≥5.
- ▸Trastuzumab plus cisplatin-fluoropyrimidine improves median OS by 2.7 months in HER2-positive disease (ToGA).
- ▸Apatinib offers a 1.8-month OS benefit over placebo in third-line therapy for chemotherapy-refractory patients.
The management of recurrent or metastatic follows a biomarker-driven approach, with first-line chemotherapy backbone determined by HER2 status and PD-L1 combined positive score (CPS).
Risk Stratification and First-Line Selection
Step 1: Determine HER2 status. Patients with HER2-positive (IHC 3+ or IHC 2+/FISH+) advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma receive plus chemotherapy. The ToGA trial established this as standard: median overall survival (OS) was 13.8 months (95% CI 12-16) with trastuzumab plus -fluoropyrimidine versus 11.1 months (10-13) with chemotherapy alone (HR 0.74, 95% CI 0.60-0.91; P=0.0046) [35]A1b. The NNT to prevent one death at median follow-up is not calculable from reported data.
Step 2: For HER2-negative disease, assess PD-L1 CPS.
| PD-L1 CPS Subgroup | Recommended First-Line Regimen | Key Efficacy Result | Source |
|---|---|---|---|
| CPS ≥5 | + fluoropyrimidine/platinum | OS HR 0.71 (95% CI 0.61-0.81); 5-year OS 16% vs 6% | CheckMate 649 [3]A1b |
| CPS ≥1 | + fluoropyrimidine/platinum | Median OS 13.0 vs 11.4 months; HR 0.74 (0.65-0.84) | KEYNOTE-859 [42]A1b |
| CPS <1 or any | Chemotherapy alone (fluoropyrimidine + platinum) | Median OS 11.5 months (placebo arm) | KEYNOTE-859 [42]A1b |
For patients with PD-L1 CPS ≥5, the CheckMate 649 5-year update confirms sustained benefit: 16% versus 6% alive at 5 years (NNT = 10) [3]A1b. Grade 3/4 treatment-related adverse events occurred in 60% of patients receiving nivolumab plus chemotherapy vs 45% with chemotherapy alone [3]A1b. In KEYNOTE-859, pembrolizumab plus chemotherapy improved median OS in the ITT population from 11.5 months to 12.9 months (HR 0.78, 95% CI 0.70-0.87; P<0.0001) [42]A1b. The most common grade 3-5 adverse events were anemia (12% vs 10%) and decreased neutrophil count (10% vs 8%) [42]A1b.
What NOT to Do in First-Line
- Do not use FAMTX or FEMTX (fluorouracil + adriamycin/ + with leucovorin rescue), these regimens showed no benefit over surgery alone in the adjuvant setting (5-year OS 43% vs 44%; HR 0.98, P=0.86) [39]A1a.
- Do not omit immunotherapy for PD-L1 CPS ≥5 patients without contraindications, as the absolute OS benefit at 5 years is 10% [3]A1b.
Second-Line Therapy
After progression on first-line platinum-fluoropyrimidine, second-line options include -based chemotherapy with or without . The K-Umbrella umbrella trial used paclitaxel (with or without ramucirumab) as standard-of-care control; median OS was 8.7 months in the control group [44]A1b. However, the RINDBeRG trial demonstrated that continuing ramucirumab beyond progression with did not improve OS compared with irinotecan alone (median OS 9.4 vs 8.5 months; adjusted HR 0.91, 95% CI 0.74-1.13; P=0.49) [14]A1b. Therefore, routine continuation of antiangiogenic therapy beyond progression is not recommended.
For patients with peritoneal metastasis, the PHOENIX-GC trial compared intraperitoneal (IP) paclitaxel plus S-1 versus cisplatin plus S-1. Median survival was 17.7 months vs 15.2 months (HR 0.72, 95% CI 0.49-1.04), failing to show statistical superiority [10]A1b. After adjustment for baseline , HR was 0.59 (95% CI 0.39-0.87) [10]A1b. The 3-year OS rate was 21.9% vs 6.0% [10]A1b.
Third-Line and Beyond
Apatinib (a VEGFR2 TKI) is approved for chemotherapy-refractory advanced gastric cancer. In a phase III trial, apatinib 850 mg daily improved median OS from 4.7 months (placebo) to 6.5 months (HR 0.709, 95% CI 0.537-0.937) and median PFS from 1.8 to 2.6 months (HR 0.444, 95% CI 0.331-0.595) [15]A1b. Common grade 3-4 toxicities included , proteinuria, and [15]A1b.
Special Considerations: Peritoneal Metastasis and HIPEC
The GASTRIPEC-I trial evaluated cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer with synchronous peritoneal metastases. Median OS was 14.9 months in both groups (HR 0.72, 95% CI 0.39-1.32) [7]A1b. However, PFS was significantly improved: 3.5 months with CRS alone vs 7.1 months with CRS+HIPEC [7]A1b. In the subgroup achieving complete cytoreduction (CCR0), HIPEC significantly improved OS [7]A1b. HIPEC did not increase surgical complications [7]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Role of postoperative chemoradiotherapy after D2 resection | Adjuvant chemotherapy alone is superior (ARTIST 2 [4]A1b, CRITICS per-protocol [27]A1b) | Adjuvant chemoradiotherapy may be considered for high-risk patients | Category 1 (ESMO) for CT alone | After D2 , chemotherapy alone is preferred; radiotherapy adds toxicity without recurrence reduction [4]A1b[27]A1b |
| Continuation of antiangiogenic therapy beyond progression | Not recommended (RINDBeRG negative) [14]A1b | Hypothetical benefit based on other tumor types | Level 1 evidence against | Do not continue ramucirumab after first-line progression [14]A1b |
Pearl: For first-line HER2-negative advanced gastric cancer, always check PD-L1 CPS, if ≥5, nivolumab plus chemotherapy provides a 10% absolute OS benefit at 5 years (NNT=10) [3]A1b; for HER2-positive disease, trastuzumab plus platinum-fluoropyrimidine remains the standard [35]A1b.
| Biomarker | Recommended Regimen | Key Result | Reference |
|---|---|---|---|
| HER2+ | Trastuzumab + cisplatin + capecitabine/5-FU | Median OS 13.8 vs 11.1 months; HR 0.74 | [35]A1b |
| HER2-, PD-L1 CPS ≥5 | Nivolumab + fluoropyrimidine/platinum | 5-year OS 16% vs 6%; HR 0.71 | [3]A1b |
| HER2-, PD-L1 CPS ≥1 | Pembrolizumab + fluoropyrimidine/platinum | Median OS 13.0 vs 11.4 months; HR 0.74 | [42]A1b |
| HER2-, any PD-L1 | Fluoropyrimidine + platinum alone | Median OS 11.5 months | [42]A1b |
Targeted and Immune Therapy
- ▸Trastuzumab deruxtecan is the standard third-line therapy for HER2-positive advanced gastric cancer, with an objective response rate of 51% and overall survival benefit (HR 0.59) [52].
- ▸Pembrolizumab plus chemotherapy improves overall survival in first-line HER2-negative advanced gastric cancer, with greater benefit at higher PD-L1 CPS [42].
- ▸Bevacizumab improves progression-free survival but not overall survival in advanced gastric cancer and is not recommended in the perioperative setting due to increased anastomotic leaks [50][57].
Building on the chemotherapy backbone, the addition of targeted agents and immune checkpoint inhibitors has reshaped treatment paradigms across all stages of . Biomarker testing for HER2, PD-L1 combined positive score (CPS), and microsatellite instability (MSI) status is now mandatory before initiating systemic therapy [46]A1c.
HER2-Directed Therapy
plus chemotherapy remains the standard first-line regimen for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The phase III KEYNOTE-811 trial demonstrated that adding to trastuzumab and chemotherapy further improves progression-free survival and overall survival without compromising health-related quality of life [54]A1b. In the primary analysis, the pembrolizumab combination showed a significant survival benefit; patient-reported outcomes were maintained, with 71.9% of patients in the pembrolizumab group reporting improved or stable global health status at week 24 versus 71.5% in the placebo group [54]A1b. A single-arm phase II trial of first-line pembrolizumab plus trastuzumab and chemotherapy achieved a 6-month progression-free survival rate of 70% (95% CI 54-83), meeting its prespecified efficacy threshold [62]B2b.
Trastuzumab deruxtecan (T-DXd) is the standard third-line therapy for HER2-positive advanced gastric cancer. In the randomized phase II DESTINY-Gastric01 trial, T-DXd 6.4 mg/kg every 3 weeks produced an objective response rate of 51% versus 14% with physician's choice chemotherapy (P<0.001) and improved median overall survival (12.5 vs 8.4 months; HR 0.59, 95% CI 0.39-0.88; P=0.01) [52]B2b. Grade ≥3 neutropenia occurred in 51% of T-DXd recipients, and or pneumonitis was reported in 12 patients (9.6%), including three with grade 3-4 events [52]B2b.
Immune Checkpoint Inhibitors
Pembrolizumab plus chemotherapy is a first-line option for HER2-negative advanced gastric/GEJ adenocarcinoma. In KEYNOTE-859, pembrolizumab 200 mg every 3 weeks plus investigator's choice of fluoropyrimidine/platinum chemotherapy significantly improved median overall survival versus placebo plus chemotherapy in the intention-to-treat population (12.9 vs 11.5 months; HR 0.78, 95% CI 0.70-0.87; P<0.0001) [42]A1b. The benefit was greater in patients with PD-L1 CPS ≥10 (median OS 15.7 vs 11.8 months; HR 0.65, 95% CI 0.53-0.79) [42]A1b. Grade 3-5 adverse events were similar between arms; serious treatment-related adverse events occurred in 23% of the pembrolizumab group versus 19% of the placebo group [42]A1b.
In KEYNOTE-062, pembrolizumab monotherapy was noninferior to chemotherapy for overall survival in patients with PD-L1 CPS ≥1 (median 10.6 vs 11.1 months; HR 0.91, 99.2% CI 0.69-1.18) and showed a trend toward improved survival in the CPS ≥10 subgroup (median 17.4 vs 10.8 months; HR 0.69, 95% CI 0.49-0.97) [49]A1b. Pembrolizumab plus chemotherapy was not superior to chemotherapy alone for the primary endpoints [49]A1b. Health-related quality of life was maintained with pembrolizumab, with longer time to deterioration in nausea/vomiting compared with chemotherapy (HR 0.61, 95% CI 0.44-0.85; P=0.003) [55]A1b.
Tumor mutational burden (TMB) is an independent predictor of pembrolizumab efficacy beyond PD-L1 status. In the KEYNOTE-061 exploratory analysis, whole-exome sequencing TMB was significantly associated with objective response rate, progression-free survival, and overall survival in pembrolizumab-treated patients (all P<0.001) but not in -treated patients (all P>0.6) [47]A1b. The area under the ROC curve for TMB and response was 0.68 for pembrolizumab versus 0.51 for paclitaxel [47]A1b.
Adjuvant immunotherapy has not shown benefit in resected high-risk disease. The VESTIGE trial randomized patients with ypN+ and/or R1 status after neoadjuvant chemotherapy and surgery to / versus chemotherapy. The trial was stopped for futility; median disease-free survival was 11.4 months with immunotherapy versus 20.8 months with chemotherapy (HR 1.55, 95% CI 1.07-2.25) [17]B2b.
Perioperative immunotherapy remains investigational. In KEYNOTE-585, neoadjuvant/adjuvant pembrolizumab plus chemotherapy significantly improved pathologic complete response (pCR) rate (13.9% vs 2.8%; difference 10.9%, 95% CI 7.5-14.8) but did not achieve a statistically significant improvement in event-free survival (HR 0.81, 95% CI 0.67-0.99; P=0.0198) [30]A1b. A meta-analysis of neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors reported a pooled pCR rate of 29% and an R0 resection rate of 100%, with a pCR rate of 51% in patients with PD-L1 CPS ≥5 [53]A1a.
Anti-Angiogenic Therapy
added to first-line chemotherapy in advanced gastric cancer improved progression-free survival and response rate but did not prolong overall survival. In the AVAGAST trial, median overall survival was 12.1 months with bevacizumab plus - versus 10.1 months with placebo (HR 0.87, 95% CI 0.73-1.03) [50]A1b. Progression-free survival was significantly improved (6.7 vs 5.3 months; HR 0.80, 95% CI 0.68-0.93) and overall response rate was higher (46.0% vs 37.4%) [50]A1b. Biomarker analysis suggested that high baseline plasma VEGF-A levels and low tumor neuropilin-1 expression may predict bevacizumab benefit, particularly in non-Asian patients [51]A1b.
In the perioperative setting, the ST03 trial found no survival benefit from adding bevacizumab to , cisplatin, and capecitabine chemotherapy (3-year overall survival 48.1% vs 50.3%; HR 1.08, 95% CI 0.91-1.29) and increased wound healing complications and anastomotic leaks, leading to early termination of recruitment for junctional tumors [57]B2b.
Emerging Agents
Favezelimab, an anti-LAG-3 antibody, is under investigation in combination with pembrolizumab. Population pharmacokinetic and exposure-response analyses in gastric cancer patients showed that increasing favezelimab exposures were associated with increased objective response rate without a significant effect on safety [61]C4.
Alternate promoter utilization is a novel mechanism of immune evasion. In metastatic gastric cancer, tumors with high alternate promoter utilization exhibited lower T-cell cytolytic activity and lower response rates to PD-1 inhibitors (8% vs 42%; P=0.03), and median progression-free survival was 55 versus 180 days (P=0.0076) [56]B2b.
| Trial | Setting | Regimen | Key Efficacy Result | Safety Signal |
|---|---|---|---|---|
| KEYNOTE-859 [42]A1b | First-line advanced HER2- | Pembrolizumab + chemo vs placebo + chemo | OS: 12.9 vs 11.5 mo; HR 0.78 | Grade 3-5 anemia 12% vs 10% |
| KEYNOTE-062 [49]A1b | First-line advanced PD-L1 CPS≥1 | Pembrolizumab vs chemo | OS noninferior; CPS≥10: 17.4 vs 10.8 mo; HR 0.69 | Grade 3-5 TRAE 17% vs 69% |
| KEYNOTE-811 [54]A1b | First-line advanced HER2+ | Pembrolizumab + trastuzumab + chemo vs placebo + trastuzumab + chemo | Improved PFS and OS (primary analysis) | No negative QoL impact |
| AVAGAST [50]A1b | First-line advanced | Bevacizumab + chemo vs placebo + chemo | OS: 12.1 vs 10.1 mo; HR 0.87 (NS); PFS: 6.7 vs 5.3 mo; HR 0.80 | Neutropenia 35% vs 37% |
| ST03 [57]B2b | Perioperative resectable | Bevacizumab + ECF chemo vs ECF alone | 3-yr OS 48.1% vs 50.3%; HR 1.08 | 24% vs 10% |
| VESTIGE [17]B2b | Adjuvant ypN+/R1 | Nivolumab/ipilimumab vs chemo | DFS: 11.4 vs 20.8 mo; HR 1.55 | No excess toxicity |
| KEYNOTE-585 [30]A1b | Perioperative locally advanced | Pembrolizumab + chemo vs placebo + chemo | pCR 13.9% vs 2.8%; EFS HR 0.81 (NS) | No new signals |
Pearl: In first-line HER2-negative advanced gastric cancer, pembrolizumab plus chemotherapy provides a modest but significant overall survival benefit (HR 0.78) that is most pronounced in patients with PD-L1 CPS ≥10 (HR 0.65); always check PD-L1 CPS, MSI, and HER2 before selecting therapy [42]A1b[46]A1c.
Toxicity and Supportive Care
- ▸CIPN is highly prevalent and negatively impacts quality of life; early recognition and dose modification are critical.
- ▸Cardiotoxicity risk is highest with anti-VEGFR TKIs and ramucirumab; baseline and periodic cardiac monitoring is warranted.
- ▸Hand-foot syndrome and diarrhea are common with fluoropyrimidine-based regimens and require proactive supportive care.
Beyond the efficacy of targeted and immune therapies, their toxicity profiles require active management alongside those of conventional chemotherapy. The most clinically significant toxicities include neutropenia and febrile neutropenia, chemotherapy-induced (CIPN), cardiotoxicity, and other regimen-specific adverse events.
Neutropenia and Febrile Neutropenia
Neutropenia is the most common dose-limiting toxicity across platinum-fluoropyrimidine and taxane-based regimens. In the phase III SOX versus CS trial, grade 3 or higher neutropenia occurred in 19.5% of patients receiving S-1 plus (SOX) compared with 41.8% receiving plus S-1 (CS) [24]A1b. Febrile neutropenia was significantly lower with SOX (0.9% vs 6.9%) [24]A1b. Among patients receiving weekly as second-line therapy, grade 3-4 neutropenia developed in 28.7% of patients, and grade 3-4 anemia in 21.3% [66]A1b. In the -oxaliplatin-fluorouracil (TEF) regimen, febrile neutropenia was reported in only 2% of patients, compared with 14% with docetaxel-oxaliplatin (TE) and 9% with docetaxel-oxaliplatin- (TEX) [67]B2b. A reduced-dose docetaxel plus capecitabine regimen produced grade 3-4 neutropenia in 36% of patients, with no treatment-related deaths [76]B2b.
Risk factors for febrile neutropenia include chronic comorbidities. In a large cohort study, chronic obstructive pulmonary disease (HR 1.30), congestive heart failure (HR 1.43), HIV infection (HR 3.40), autoimmune disease (HR 2.01), (HR 1.57), renal disease (HR 1.60), and thyroid disorder (HR 1.32) were all associated with significantly increased FN risk [63]B3b. These factors should be considered when selecting chemotherapy intensity and the need for primary prophylaxis with granulocyte colony-stimulating factor.
Interestingly, neutropenia during chemotherapy may be a prognostic marker. In patients receiving weekly paclitaxel as second-line therapy, both mild (grades 1-2) and severe (grades 3-4) neutropenia were associated with improved overall survival (HR 0.61 for both) [64]B3b. This suggests that achieving some degree of neutropenia may reflect adequate drug exposure, though dose reductions should not be withheld when febrile neutropenia or grade 4 neutropenia occurs.
Chemotherapy-Induced Peripheral Neuropathy
CIPN is a common and debilitating toxicity, particularly with oxaliplatin and taxanes. In a large prospective cohort of 2,135 patients with gastroesophageal cancer, CIPN increased significantly during treatment across all settings [5]B2b. Adjusted mean CIPN scores at 6 months were 8.3 for chemoradiotherapy (baseline 5.5), 16.0 for curative-intent chemotherapy (baseline 5.6), and 25.4 for palliative therapy (baseline 10.7) [5]B2b. After treatment, CIPN scores decreased but did not return to baseline, and CIPN was negatively correlated with health-related quality of life [5]B2b. In the SOX versus CS trial, sensory neuropathy grade 3 or higher was more common with SOX (4.7% vs 0%) [24]A1b. In the TEF/TE/TEX study, grade 3-4 sensory neuropathy occurred in 14% of patients overall [67]B2b. Early recognition and dose modification are essential to minimize long-term impairment.
Cardiotoxicity
Targeted therapies, especially anti-angiogenic agents, carry a risk of cardiotoxicity. A meta-analysis of 31 trials including 28,538 patients found that the highest relative risk of high-grade cardiotoxicity was with vandetanib (RR 7.71), followed by (RR 5.0) and aflibercept (RR 4.1) [18]B2a. Among drug classes, anti-VEGFR tyrosine kinase inhibitors had the highest RR (5.62), and anti-VEGF monoclonal antibodies/VEGF-trap had an RR of 1.82 [18]B2a. The incidence of cardiotoxicity was highest in thyroid cancer (8%) and (4%) [18]B2a. In the lapatinib phase II trial, one patient experienced grade 4 cardiac ischemia/infarction, and one treatment-related death occurred due to central nervous system ischemia [74]B2b. Clinicians should monitor blood pressure, cardiac function, and symptoms of ischemia in patients receiving these agents.
Other Common Toxicities
(HFS) is characteristic of fluoropyrimidines and multikinase inhibitors. In the apatinib phase III trial, the most common grade 3-4 nonhematologic adverse events were hand-foot syndrome, proteinuria, and [15]A1b. In the docetaxel-capecitabine regimen, HFS occurred in 53% of patients (all grades) [76]B2b. Diarrhea is frequent with and fluoropyrimidines: grade 3-4 diarrhea was reported in 13% of patients in the TEF/TE/TEX study [67]B2b and in 3.1% of patients receiving adjuvant S-1 [71]A1b. Anorexia and fatigue are also common: grade 3-4 anorexia occurred in 17.3% of patients receiving irinotecan [66]A1b and in 6.0% of patients receiving adjuvant S-1 [71]A1b; grade 3-4 fatigue was reported in 21% of patients in the TEF/TE/TEX study [67]B2b.
| Complication | Frequency (selected regimens) | Prevention | Management |
|---|---|---|---|
| Neutropenia (grade 3-4) | SOX 19.5%, CS 41.8%, paclitaxel 28.7%, docetaxel-capecitabine 36% [24]A1b[66]A1b[76]B2b | Consider G-CSF prophylaxis in high-risk patients (comorbidities [63]B3b) | Dose delay, reduction, or G-CSF; hold for febrile neutropenia |
| Febrile neutropenia | SOX 0.9%, CS 6.9%, TEF 2%, TE 14%, TEX 9% [24]A1b[67]B2b | Primary prophylaxis if high risk | Hospitalization, broad-spectrum , G-CSF |
| Sensory neuropathy (grade 3-4) | SOX 4.7%, CS 0%, TEF/TE/TEX 14% [24]A1b[67]B2b | Limit cumulative oxaliplatin dose; monitor symptoms | Dose reduction, switch to non-neurotoxic agent |
| Cardiotoxicity (high-grade) | RR 5.62 for anti-VEGFR TKIs; incidence 4% in gastric cancer [18]B2a | Baseline cardiac assessment; monitor BP, ECG | Hold or discontinue offending agent; cardiology consultation |
| Hand-foot syndrome (all grades) | Docetaxel-capecitabine 53% [76]B2b; apatinib (grade 3-4) [15]A1b | Emollients, avoid heat/friction | Dose interruption, , pyridoxine |
| Diarrhea (grade 3-4) | TEF/TE/TEX 13% [67]B2b; adjuvant S-1 3.1% [71]A1b | Loperamide prophylaxis for irinotecan | Aggressive hydration, loperamide, octreotide if severe |
| Anorexia (grade 3-4) | Irinotecan 17.3% [66]A1b; adjuvant S-1 6.0% [71]A1b | Nutritional support, antiemetics | Dose reduction, appetite stimulants |
Pearl: Neutropenia during chemotherapy for advanced gastric cancer is associated with improved survival, but febrile neutropenia requires prompt management; comorbidities significantly increase risk and should guide G-CSF prophylaxis decisions.
Special Populations
- ▸Pretreatment cachexia (48% prevalence) is independently associated with decreased overall survival; early dietetic consultation reduces weight loss.
- ▸Poor performance status, high NLR (>3), and elevated mGPS are consistent independent prognostic factors across treatment settings.
- ▸Pre-existing anti-thyroglobulin and anti-thyroid peroxidase antibodies predict ICI-induced thyroid dysfunction but comprehensive autoantibody screening has limited utility for other irAEs.
Beyond managing treatment-related toxicity, clinicians must account for patient-specific factors that modify treatment tolerance and outcomes. Three domains, cachexia, performance status, and autoimmune comorbidity, carry particular weight in systemic therapy.
Cachexia and Nutritional Support
Pretreatment cachexia, defined as >5% half-year weight loss or >2% in patients with BMI <20 kg/m², affects 48% of patients with esophagogastric cancer and is independently associated with decreased overall survival (HR 1.52, 95% CI 1.11-2.09) [77]B2b. Despite this, more than one-third of patients with cachexia are not referred for dietetic consultation at baseline. Among those who are referred, median weight loss at 3 months is significantly lower (0% vs 2%) [77]B2b. The modified Glasgow prognostic score (mGPS), derived from C-reactive protein and albumin, is strongly prognostic for overall survival and correlates with sarcopenia on CT imaging [80]A1b. These findings support routine nutritional screening and early dietetic referral as standard components of pretreatment assessment.
Performance Status and Prognostic Stratification
Poor performance status is a consistent independent predictor of inferior survival across treatment settings. In the REAL-2 meta-analysis, performance status was an independent predictor of poor survival [79]B2a. In JCOG9912, performance status ≥1 carried an HR of 1.45 (95% CI 1.13-1.86) for overall survival [29]A1b. For patients receiving first-line PD-1 blockade, PS ≥2 predicts worse outcomes [88]B3b. The neutrophil-to-lymphocyte ratio (NLR) >3.0 also carries independent prognostic value: in REAL-2, high NLR was associated with an HR for OS of 1.73 (95% CI 1.50-2.00) and median OS of 9.1 vs 12.7 months [21]A1b. Baseline health-related quality-of-life scales, particularly worse social functioning (HR 2.20) and nausea (HR 1.89), are significantly associated with worse event-free and overall survival in the CRITICS trial [78]A1b. A recently developed nomogram for HER2-negative metastatic gastric cancer receiving first-line PD-1 blockade integrates ECOG PS, pleural or peritoneal metastases, Lauren type, C-reactive protein, and elevated lactate dehydrogenase, and stratifies patients into three risk groups with distinct survival outcomes [88]B3b.
Autoimmune Disease and Immune Checkpoint Inhibitors
Pre-existing anti-thyroglobulin and anti-thyroid peroxidase antibodies are risk factors for immune checkpoint inhibitor-induced thyroid dysfunction (39.5% vs 12.5% in antibody-positive vs negative patients; P<0.01) [89]B3b. Comprehensive measurement of other autoimmune disease-related antibodies (anti-nuclear, anti-GAD, anti-AchR) has limited utility for predicting other immune-related adverse events [89]B3b.
Other Considerations
Age <60 years was an independent predictor of poor survival in the REAL-2 meta-analysis, though the mechanism is unclear [79]B2a. Diffuse-type histology is associated with worse event-free and overall survival compared with intestinal type (HR 1.94) [78]A1b. Patients with significant renal or hepatic impairment were excluded from the pivotal trials reviewed; therefore, data guiding dose modifications in these populations are lacking, and standard organ-function eligibility criteria should be applied.
Pearl: Pretreatment cachexia affects nearly half of patients and independently predicts survival; early dietetic referral reduces weight loss and should be a standard component of baseline assessment.
Related Pages
Part of the Gastric Cancer family. Cross-cutting management is split across dedicated child pages:
- , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
- Gastric Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
- Gastric Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
- Gastric Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
- Gastric Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
- Gastric Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease
Pearl: Use these links to hop between management modalities; the parent Gastric Cancer page carries diagnosis + staging that informs every decision here.
References
- [1]
Kim HS, Kim HJ, Kim SY et al.. “Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23942775 ↗
L2SR_COHORTCited in: Setting-Based Framework - [2]
Singh PP, Singh S. “Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23599253 ↗
L2SR_COHORTCited in: Setting-Based Framework - [3]
Janjigian YY, Shitara K, Ajani JA et al.. “Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41687718 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens - [4]
Park SH, Lim DH, Sohn TS et al.. “A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33278599 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens - [5]
van Velzen MJM, Pape M, Sprangers MAG et al.. “Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38977016 ↗
L2PROSPECTIVE_COHORTCited in: Setting-Based Framework, Toxicity and Supportive Care - [6]
Pietrantonio F, Miceli R, Raimondi A et al.. “Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31513484 ↗
L2SR_COHORTCited in: Setting-Based Framework - [7]
Rau B, Lang H, Koenigsrainer A et al.. “Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37906724 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens - [8]
Kang YK, Yook JH, Park YK et al.. “PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34133211 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Special Populations - [9]
Yoshida K, Kodera Y, Kochi M et al.. “Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30925125 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens - [10]
Ishigami H, Fujiwara Y, Fukushima R et al.. “Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29746229 ↗
L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens - [11]
Smalley SR, Benedetti JK, Haller DG et al.. “Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22585691 ↗
L1RCTCited in: Setting-Based Framework, Concurrent Chemotherapy with RT, Chemotherapy Regimens - [12]
Kang YK, Kim HD, Yook JH et al.. “Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38996201 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens - [13]
Li C, Tian Y, Zheng Y et al.. “Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39383487 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens - [14]
Sakai D, Kadowaki S, Kawabata R et al.. “Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40408613 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens - [15]
Li J, Qin S, Xu J et al.. “Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26884585 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Toxicity and Supportive Care - [16]
Sahin U, Türeci Ö, Manikhas G et al.. “FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33610734 ↗
L2RCT_PHASE2Cited in: Setting-Based Framework - [17]
Lordick F, Mauer ME, Stocker G et al.. “Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39542422 ↗
L2RCT_PHASE2Cited in: Setting-Based Framework, Targeted and Immune Therapy - [18]
Santoni M, Guerra F, Conti A et al.. “Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.” Cancer treatment reviews (2017). PMID: 28818671 ↗
L2SR_COHORTCited in: Setting-Based Framework, Toxicity and Supportive Care - [19]
Schwengber WK, Pereira RA, Leite da Silva LF et al.. “Neoadjuvant immune checkpoint inhibitors for localized dMMR/MSI-H gastric cancer: a meta-analysis.” ESMO open (2026). PMID: 41687159 ↗
L4SR_COHORTCited in: Setting-Based Framework - [20]
Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo ML et al.. “On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27799509 ↗
L3COHORTCited in: Setting-Based Framework - [21]
Grenader T, Waddell T, Peckitt C et al.. “Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26787231 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Special Populations - [22]
Ajani JA, Abramov M, Bondarenko I et al.. “A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28911091 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Special Populations - [23]
Fazio N, Biffi R, Maibach R et al.. “Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26712905 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [24]
Yamada Y, Higuchi K, Nishikawa K et al.. “Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25316259 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Toxicity and Supportive Care, Special Populations - [25]
Ryu MH, Baba E, Lee KH et al.. “Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26216386 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [26]
Bajetta E, Floriani I, Di Bartolomeo M et al.. “Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24728035 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [27]
de Steur WO, van Amelsfoort RM, Hartgrink HH et al.. “Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33227408 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens - [28]
Dank M, Zaluski J, Barone C et al.. “Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18558665 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [29]
Yamada Y, Boku N, Nishina T et al.. “Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23884439 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Special Populations - [30]
Shitara K, Bang YJ, Wyrwicz LS et al.. “Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.” ESMO open (2026). PMID: 41747585 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Targeted and Immune Therapy - [31]
Fujitani K, Yang HK, Mizusawa J et al.. “Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.” The Lancet. Oncology (2016). PMID: 26822397 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [32]
Cunningham D, Allum WH, Stenning SP et al.. “Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.” The New England journal of medicine (2006). PMID: 16822992 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [33]
Wang X, Yan O, Zhou J et al.. “Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42295761 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [34]
Liu X, Jin J, Zhou M et al.. “Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China.” Cancer communications (London, England) (2026). PMID: 41625476 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [35]
Bang YJ, Van Cutsem E, Feyereislova A et al.. “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.” Lancet (London, England) (2010). PMID: 20728210 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens - [36]
Park SH, Sohn TS, Lee J et al.. “Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25559811 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [37]
Fuchs CS, Niedzwiecki D, Mamon HJ et al.. “Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28976791 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [38]
Lee J, Lim DH, Kim S et al.. “Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 22184384 ↗
L1RCTCited in: Concurrent Chemotherapy with RT - [39]
Nitti D, Wils J, Dos Santos JG et al.. “Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16293676 ↗
L1SR_MA_RCTCited in: Chemotherapy Regimens - [40]
Chau I, Norman AR, Cunningham D et al.. “The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19164454 ↗
L1SR_MA_RCTCited in: Chemotherapy Regimens, Toxicity and Supportive Care - [41]
Liu R, Zhao J, Zhang R et al.. “Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41571045 ↗
L1RCTCited in: Chemotherapy Regimens - [42]
Rha SY, Oh DY, Yañez P et al.. “Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37875143 ↗
L1RCTCited in: Chemotherapy Regimens, Targeted and Immune Therapy, Special Populations - [43]
Lu Z, Cai X, Yang C et al.. “Comparative safety of postoperative HIPEC with recombinant mutant TNF-α versus paclitaxel for gastric cancer peritoneal metastasis: a randomized controlled trial.” Surgical oncology (2026). PMID: 42391679 ↗
L1RCTCited in: Chemotherapy Regimens - [44]
Lee CK, Kim HS, Jung M et al.. “Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37883723 ↗
L1RCTCited in: Chemotherapy Regimens, Toxicity and Supportive Care - [45]
Moehler M, Xiao H, Blum SI et al.. “Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37713657 ↗
L1RCTCited in: Chemotherapy Regimens - [46]
Ajani JA, D'Amico TA, Bentrem DJ et al.. “Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35130500 ↗
L1GUIDELINECited in: Targeted and Immune Therapy - [47]
Shitara K, Özgüroğlu M, Bang YJ et al.. “Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34082019 ↗
L1RCTCited in: Targeted and Immune Therapy - [48]
Jeung HC, Moon YW, Rha SY et al.. “Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18029971 ↗
L1RCTCited in: Targeted and Immune Therapy - [49]
Shitara K, Van Cutsem E, Bang YJ et al.. “Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.” JAMA oncology (2020). PMID: 32880601 ↗
L1RCTCited in: Targeted and Immune Therapy - [50]
Ohtsu A, Shah MA, Van Cutsem E et al.. “Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21844504 ↗
L1RCTCited in: Targeted and Immune Therapy - [51]
Van Cutsem E, de Haas S, Kang YK et al.. “Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22565005 ↗
L1RCTCited in: Targeted and Immune Therapy - [52]
Shitara K, Bang YJ, Iwasa S et al.. “Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.” The New England journal of medicine (2020). PMID: 32469182 ↗
L2RCT_PHASE2Cited in: Targeted and Immune Therapy - [53]
Ma X, Guo W, Sun J et al.. “Efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophagogastric junction or gastric cancer: a systematic review and meta analysis.” Frontiers in immunology (2026). PMID: 42292472 ↗
L1SR_MA_RCTCited in: Targeted and Immune Therapy - [54]
Janjigian YY, Kawazoe A, Xu J et al.. “Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial.” ESMO open (2025). PMID: 41033280 ↗
L1RCTCited in: Targeted and Immune Therapy - [55]
Van Cutsem E, Valderrama A, Bang YJ et al.. “Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.” ESMO open (2021). PMID: 34371381 ↗
L1RCTCited in: Targeted and Immune Therapy - [56]
Sundar R, Huang KK, Qamra A et al.. “Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30624548 ↗
L2NON_RANDOMIZED_TRIALCited in: Targeted and Immune Therapy - [57]
Cunningham D, Stenning SP, Smyth EC et al.. “Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.” The Lancet. Oncology (2017). PMID: 28163000 ↗
L2RCT_PHASE2Cited in: Targeted and Immune Therapy - [58]
Shah MA, Jhawer M, Ilson DH et al.. “Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 21189380 ↗
L2NON_RANDOMIZED_TRIALCited in: Targeted and Immune Therapy - [59]
Birch-Ford J, Crosby B, Langford G et al.. “Real-Life Outcomes of First-Line Palliative Chemoimmunotherapy in Oesophago-Gastric Cancers: A Multi-Centre Retrospective Cohort Study.” Cancers (2026). PMID: 42192886 ↗
L4PROSPECTIVE_COHORTCited in: Targeted and Immune Therapy - [60]
Keefe SM, Hoffman-Censits J, Cohen RB et al.. “Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27457310 ↗
L4PHASE_1_TRIALCited in: Targeted and Immune Therapy - [61]
Gaurav M, Barcomb H, Maxwell KF et al.. “Population Pharmacokinetic, Exposure-Response Efficacy and Safety Analyses of Favezelimab in Patients With Solid Tumors.” Clinical and translational science (2026). PMID: 42397055 ↗
L4PHASE_1_TRIALCited in: Targeted and Immune Therapy - [62]
Janjigian YY, Maron SB, Chatila WK et al.. “First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.” The Lancet. Oncology (2020). PMID: 32437664 ↗
L2NON_RANDOMIZED_TRIALCited in: Targeted and Immune Therapy - [63]
Chao C, Page JH, Yang SJ et al.. “History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24915871 ↗
L3COHORTCited in: Toxicity and Supportive Care - [64]
Shitara K, Matsuo K, Takahari D et al.. “Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20494962 ↗
L3COHORTCited in: Toxicity and Supportive Care - [65]
Kang JH, Lee SI, Lim DH et al.. “Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22412140 ↗
L1RCTCited in: Toxicity and Supportive Care, Special Populations - [66]
Hironaka S, Ueda S, Yasui H et al.. “Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24190112 ↗
L1RCTCited in: Toxicity and Supportive Care - [67]
Van Cutsem E, Boni C, Tabernero J et al.. “Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25416687 ↗
L2RCT_PHASE2Cited in: Toxicity and Supportive Care - [68]
Van Cutsem E, Bang YJ, Mansoor W et al.. “A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 29177434 ↗
L2RCT_PHASE2Cited in: Toxicity and Supportive Care - [69]
Scartozzi M, Bittoni A, Pistelli M et al.. “Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives.” Cancer treatment reviews (2009). PMID: 19467788 ↗
L2SR_COHORTCited in: Toxicity and Supportive Care - [70]
Boku N, Yamamoto S, Fukuda H et al.. “Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.” The Lancet. Oncology (2009). PMID: 19818685 ↗
L1RCTCited in: Toxicity and Supportive Care - [71]
Sakuramoto S, Sasako M, Yamaguchi T et al.. “Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.” The New England journal of medicine (2007). PMID: 17978289 ↗
L1RCTCited in: Toxicity and Supportive Care - [72]
Pavlakis N, Shitara K, Sjoquist K et al.. “INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39365958 ↗
L2RCT_PHASE2Cited in: Toxicity and Supportive Care - [73]
Pavlakis N, Sjoquist KM, Martin AJ et al.. “Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27325864 ↗
L2RCT_PHASE2Cited in: Toxicity and Supportive Care - [74]
Iqbal S, Goldman B, Fenoglio-Preiser CM et al.. “Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21415234 ↗
L2NON_RANDOMIZED_TRIALCited in: Toxicity and Supportive Care - [75]
Chan JA, Blaszkowsky LS, Enzinger PC et al.. “A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21217058 ↗
L2NON_RANDOMIZED_TRIALCited in: Toxicity and Supportive Care - [76]
Rosati G, Bilancia D, Germano D et al.. “Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591806 ↗
L2NON_RANDOMIZED_TRIALCited in: Toxicity and Supportive Care - [77]
Dijksterhuis WPM, Latenstein AEJ, van Kleef JJ et al.. “Cachexia and Dietetic Interventions in Patients With Esophagogastric Cancer: A Multicenter Cohort Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33418527 ↗
L2PROSPECTIVE_COHORTCited in: Special Populations - [78]
van Amelsfoort RM, Walraven I, Kieffer J et al.. “Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35276669 ↗
L1RCTCited in: Special Populations - [79]
Okines AFC, Norman AR, McCloud P et al.. “Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19474114 ↗
L2SR_COHORTCited in: Special Populations - [80]
Hacker UT, Hasenclever D, Baber R et al.. “Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35395383 ↗
L1RCTCited in: Special Populations - [81]
Kang YK, Ryu MH, Park SH et al.. “Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29438463 ↗
L1RCTCited in: Special Populations - [82]
Al-Batran SE, Van Cutsem E, Oh SC et al.. “Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26747859 ↗
L1RCTCited in: Special Populations - [83]
Fuchs CS, Shitara K, Di Bartolomeo M et al.. “Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2019). PMID: 30718072 ↗
L1RCTCited in: Special Populations - [84]
Robak T, Jin J, Pylypenko H et al.. “Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.” The Lancet. Oncology (2018). PMID: 30348538 ↗
L1RCTCited in: Special Populations - [85]
Cats A, Jansen EPM, van Grieken NCT et al.. “Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.” The Lancet. Oncology (2018). PMID: 29650363 ↗
L1RCTCited in: Special Populations - [86]
Shah MA, Janjigian YY, Stoller R et al.. “Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26438119 ↗
L2RCT_PHASE2Cited in: Special Populations - [87]
Roth AD, Fazio N, Stupp R et al.. “Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17664469 ↗
L2RCT_PHASE2Cited in: Special Populations - [88]
Fu B, Zhang M, Fang T et al.. “Prognostic nomogram for patients with HER2-negative metastatic gastric cancer receiving first-line PD-1 blockade.” ESMO open (2026). PMID: 41650749 ↗
L3RETROSPECTIVE_COHORTCited in: Special Populations - [89]
Izawa N, Shiokawa H, Onuki R et al.. “The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.” ESMO open (2022). PMID: 35247869 ↗
L3COHORTCited in: Special Populations